<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02819908</url>
  </required_header>
  <id_info>
    <org_study_id>BF-2015-011</org_study_id>
    <nct_id>NCT02819908</nct_id>
  </id_info>
  <brief_title>Dropless™ vs. Less Drops™ Pharmaceutical Regimens After Cataract Surgery</brief_title>
  <official_title>Dropless™ vs. Less Drops™ Pharmaceutical Regimens After Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eye Center of North Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eye Center of North Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the relative effectiveness of the Imprimis Dropless™ (TriMoxiVanc) intraocular&#xD;
      solution with the Less Drops™ topical formulation of PredMoxiKeterolac (given for the first&#xD;
      week post op) followed by PredKeterolac (given for weeks 2 to 4 after surgery).&#xD;
&#xD;
      The hypothesis is that the &quot;dropless&quot; regimen will be non-inferior to the &quot;less drops&quot;&#xD;
      regimen in terms of post-operative IOP changes, post-operative healing, and visual quality.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Modern cataract surgery has become a relatively short out-patient procedure with small&#xD;
      incisions and short post-operative recovery time. Surgery can be influenced by surgical&#xD;
      technique and experience. Prophylactic pharmaceutical regimens are designed to control&#xD;
      post-operative pain and to reduce the potential for inflammation (i.e. macular edema, CME)&#xD;
      and infection (i.e. endophthalmitis).&#xD;
&#xD;
      The most serious potential infection related to cataract surgery is endophthalmitis.&#xD;
      Endophthalmitis is a result of microorganisms entering the eye, either during the surgical&#xD;
      procedure or before surgical incisions have healed completely. The risk of infection can be&#xD;
      reduced in several ways. Pre-operatively, reducing the bacteria on the cornea and ocular&#xD;
      adnexa can be helpful. During surgery, appropriate technique can reduce the potential for&#xD;
      ingress. Post-operatively, prophylactic antibiotics can eliminate organisms once they have&#xD;
      entered the eye. Topical drops, intracameral antibiotics and subconjunctival injections are&#xD;
      typical options in current use, usually selected on the basis of spectrum of coverage, cost,&#xD;
      efficacy and/or expected side effects.&#xD;
&#xD;
      With regard to inflammation, one of the most common post-operative responses is cystoid&#xD;
      macular edema (CME). Steroids and non-steroidal anti-inflammatory drugs (NSAIDs) appear&#xD;
      effective in reducing the incidence of CME, with NSAIDs posing a lower risk for IOP spikes&#xD;
      and showing greater efficacy some studies.&#xD;
&#xD;
      While there is documented evidence of the utility of prophylactic post-operative treatment&#xD;
      for pain and infection, patient compliance remains a significant concern. The regimen is&#xD;
      often complex, with multiple drops several times per day. Inability to instill the drops,&#xD;
      forgetfulness and a lack of appreciation for the importance of compliance can all be&#xD;
      contributing factors.&#xD;
&#xD;
      There are several new options to try to address the potential issues related to poor patient&#xD;
      compliance. One is referred to as &quot;dropless&quot; cataract surgery, which involves injection of a&#xD;
      multi-drug compound into the eye at time of cataract surgery; one such compound includes&#xD;
      triamcinolone acetonide, moxifloxacin hydrochloride and vancomycin (TriMoxiVanc). Another&#xD;
      alternative is to reduce the burden of the pharmaceutical regimen using a compounded topical&#xD;
      medication; this is termed &quot;less drops&quot; cataract surgery. An option in this regard is a&#xD;
      topical formulation of prednisolone acetate, moxifloxacin hydrochloride and ketorolac&#xD;
      tromethamine (PredMoxiKetorolac), given for one week post-operatively followed by a topical&#xD;
      formulation of prednisolone acetate and ketorolac tromethamine (PredKeterolac) given for&#xD;
      weeks 2 to 4 after surgery.&#xD;
&#xD;
      The purpose of this study is to evaluate the differences in performance between the dropless&#xD;
      and less-drops pharmaceutical regimens after cataract surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Change in Intraocular Pressure (IOP) From Baseline</measure>
    <time_frame>To end of study (1 month postop)</time_frame>
    <description>Based on Goldmann tonometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Corneal Thickness</measure>
    <time_frame>To end of study (1 month postop)</time_frame>
    <description>Based on corneal pachymetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slit Lamp (Cornea Exam)</measure>
    <time_frame>To end of study (1 month postop)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Subject Reporting no Eye Pain</measure>
    <time_frame>To end of study (1 month postop)</time_frame>
    <description>&quot;0&quot;( on the eye pain/discomfort scale)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline Eye Pain/Discomfort</measure>
    <time_frame>To end of study (1 month postop)</time_frame>
    <description>eye pain/discomfort scale</description>
  </other_outcome>
  <other_outcome>
    <measure>The Proportion of Subjects Reporting no Visual Symptoms (&quot;0&quot; )</measure>
    <time_frame>To end of study (1 month postop)</time_frame>
    <description>visual symptom scale</description>
  </other_outcome>
  <other_outcome>
    <measure>The Change From Baseline in Visual Symptoms</measure>
    <time_frame>To end of study (1 month postop)</time_frame>
    <description>visual symptom scale</description>
  </other_outcome>
  <other_outcome>
    <measure>The Change From Baseline in Central Corneal Thickness Measurements</measure>
    <time_frame>To end of study (1 month postop)</time_frame>
    <description>corneal pachymetry</description>
  </other_outcome>
  <other_outcome>
    <measure>The Change From Baseline in Macular Thickness Measurements</measure>
    <time_frame>To end of study (1 month postop)</time_frame>
    <description>based on optical coherence tomography (OCT) measurement</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Intraocular Lens Associated Postoperative Inflammation</condition>
  <arm_group>
    <arm_group_label>Imprimis Dropless</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TriMoxiVanc 0.2cc intravitreal one time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imprimis Less Drops</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pred Moxi, 1 drop tid for 1 week then, PredKeterolac bid for 2-4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imprimis Dropless</intervention_name>
    <description>Tri-Moxi-Vanc transzonular intravitreal injection</description>
    <arm_group_label>Imprimis Dropless</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imprimis Less Drops</intervention_name>
    <description>Pred-Moxi-Ketorolac and Pred-Ketorolac topical instillation qd postoperatively</description>
    <arm_group_label>Imprimis Less Drops</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ocular criteria must be met in both eyes.&#xD;
&#xD;
          -  Subject is undergoing bilateral cataract extraction or refractive lens exchange with&#xD;
             intraocular lens implantation.&#xD;
&#xD;
          -  Gender: Males and Females.&#xD;
&#xD;
          -  Age: 21 or older.&#xD;
&#xD;
          -  Willing and able to provide written informed consent for participation in the study.&#xD;
&#xD;
          -  Willing and able to comply with scheduled visits and other study procedures.&#xD;
&#xD;
          -  Willing and able to administer eye drops and record the times the drops were&#xD;
             instilled.&#xD;
&#xD;
          -  Scheduled to undergo standard cataract surgery or refractive lens exchange with&#xD;
             topical anesthesia in both eyes within 6-15 days of each other.&#xD;
&#xD;
          -  Potential postoperative best-corrected visual acuity of 20/30 or better.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  If any of the following exclusion criteria are applicable to the subject or either&#xD;
             eye, the subject should not be enrolled in the study.&#xD;
&#xD;
          -  Severe preoperative ocular pathology: amblyopia, rubella cataract, proliferative&#xD;
             diabetic retinopathy, shallow anterior chamber, macular edema, aniridia or iris&#xD;
             atrophy, uveitis, history of iritis, iris neovascularization, medically uncontrolled&#xD;
             glaucoma, microphthalmos or macrophthalmos, optic nerve atrophy, macular degeneration&#xD;
             (with anticipated best postoperative visual acuity less than 20/30), advanced&#xD;
             glaucomatous damage, etc.&#xD;
&#xD;
          -  Presence of epiretinal membrane.&#xD;
&#xD;
          -  Uncontrolled diabetes.&#xD;
&#xD;
          -  Use of any systemic or topical drug known to interfere with visual performance.&#xD;
&#xD;
          -  Contact lens use during the active treatment portion of the trial.&#xD;
&#xD;
          -  Any concurrent infectious/non-infectious conjunctivitis, keratitis or uveitis.&#xD;
&#xD;
          -  History of chronic intraocular inflammation.&#xD;
&#xD;
          -  History of retinal detachment.&#xD;
&#xD;
          -  Pseudoexfoliation syndrome or any other condition that has the potential to weaken the&#xD;
             zonules.&#xD;
&#xD;
          -  Previous refractive surgery.&#xD;
&#xD;
          -  Anesthesia other than topical, oral or intravenous anesthesia (i.e. retrobulbar,&#xD;
             general, etc).&#xD;
&#xD;
          -  Any clinically significant, serious or severe medical or psychiatric condition that&#xD;
             may increase the risk associated with study participation or may interfere with the&#xD;
             interpretation of study results.&#xD;
&#xD;
          -  Participation in (or current participation) any investigational drug or device trial&#xD;
             within the previous 30 days prior to the start date of this trial.&#xD;
&#xD;
          -  Intraocular conventional surgery within the past three months or intraocular laser&#xD;
             surgery within one month.&#xD;
&#xD;
        The principal investigator reserves the right to declare a patient ineligible or&#xD;
        non-evaluable based on medical evidence that indicates they are unsuitable for the trial.&#xD;
&#xD;
        Exclusion Criteria during surgery:&#xD;
&#xD;
        If any of the following exclusion criteria are applicable to the study eye, the subject&#xD;
        should not continue in the study.&#xD;
&#xD;
          -  If full dose (0.2 cc) is not delivered into the vitreous through the zonules as&#xD;
             evaluated by surgeon's direct visualization of the material in the posterior chamber&#xD;
             with lack of material in the anterior chamber and an empty syringe.&#xD;
&#xD;
          -  Significant vitreous loss.&#xD;
&#xD;
          -  Significant anterior chamber hyphema.&#xD;
&#xD;
          -  Uncontrollable intraocular pressure.&#xD;
&#xD;
          -  Zonular or capsular rupture.&#xD;
&#xD;
          -  Bag-sulcus, sulcus-sulcus or unknown placement of the haptics.&#xD;
&#xD;
          -  Suturing of incision required at time of surgery.&#xD;
&#xD;
          -  Intraocular lens tilt or decentration&#xD;
&#xD;
          -  Peri-bulbar or retro-bulbar block required during surgery.&#xD;
&#xD;
          -  Other procedure, such as pupil stretch, expanders, iris hooks during surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bret L Fisher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eye Center of North Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eye Center of North Florida</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 2, 2015</study_first_submitted>
  <study_first_submitted_qc>June 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <results_first_submitted>February 24, 2020</results_first_submitted>
  <results_first_submitted_qc>February 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 9, 2020</results_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eye Center of North Florida</investigator_affiliation>
    <investigator_full_name>Bret L. Fisher, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Capsule Opacification</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Imprimis Dropless</title>
          <description>TriMoxiVanc 0.2cc intravitreal one time&#xD;
Imprimis Dropless: Tri-Moxi-Vanc transzonular intravitreal injection</description>
        </group>
        <group group_id="P2">
          <title>Imprimis Less Drops</title>
          <description>Pred Moxi, 1 drop tid for 1 week then, PredKeterolac bid for 2-4 weeks.&#xD;
Imprimis Less Drops: Pred-Moxi-Ketorolac and Pred-Ketorolac topical instillation qd postoperatively</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Study data has been lost to natural disaster (Hurricane Micheal), therefore there is no study data that is available to report</population>
      <group_list>
        <group group_id="B1">
          <title>Imprimis Dropless</title>
          <description>TriMoxiVanc 0.2cc intravitreal one time&#xD;
Imprimis Dropless: Tri-Moxi-Vanc transzonular intravitreal injection</description>
        </group>
        <group group_id="B2">
          <title>Imprimis Less Drops</title>
          <description>Pred Moxi, 1 drop tid for 1 week then, PredKeterolac bid for 2-4 weeks.&#xD;
Imprimis Less Drops: Pred-Moxi-Ketorolac and Pred-Ketorolac topical instillation qd postoperatively</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <class_list>
            <class>
              <title>United States</title>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Change in Intraocular Pressure (IOP) From Baseline</title>
        <description>Based on Goldmann tonometry</description>
        <time_frame>To end of study (1 month postop)</time_frame>
        <population>Study data has been lost to natural disaster (Hurricane Micheal), therefore there is no study data that is available to report</population>
        <group_list>
          <group group_id="O1">
            <title>Imprimis Dropless</title>
            <description>TriMoxiVanc 0.2cc intravitreal one time&#xD;
Imprimis Dropless: Tri-Moxi-Vanc transzonular intravitreal injection&#xD;
no Adverse events</description>
          </group>
          <group group_id="O2">
            <title>Imprimis Less Drops</title>
            <description>Pred Moxi, 1 drop tid for 1 week then, PredKeterolac bid for 2-4 weeks.&#xD;
Imprimis Less Drops: Pred-Moxi-Ketorolac and Pred-Ketorolac topical instillation qd postoperatively&#xD;
No adverse events</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Intraocular Pressure (IOP) From Baseline</title>
          <description>Based on Goldmann tonometry</description>
          <population>Study data has been lost to natural disaster (Hurricane Micheal), therefore there is no study data that is available to report</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Corneal Thickness</title>
        <description>Based on corneal pachymetry</description>
        <time_frame>To end of study (1 month postop)</time_frame>
        <population>Study data has been lost to natural disaster (Hurricane Micheal), therefore there is no study data that is available to report</population>
        <group_list>
          <group group_id="O1">
            <title>Imprimis Dropless</title>
            <description>TriMoxiVanc 0.2cc intravitreal one time&#xD;
Imprimis Dropless: Tri-Moxi-Vanc transzonular intravitreal injection</description>
          </group>
          <group group_id="O2">
            <title>Imprimis Less Drops</title>
            <description>Pred Moxi, 1 drop tid for 1 week then, PredKeterolac bid for 2-4 weeks.&#xD;
Imprimis Less Drops: Pred-Moxi-Ketorolac and Pred-Ketorolac topical instillation qd postoperatively</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Corneal Thickness</title>
          <description>Based on corneal pachymetry</description>
          <population>Study data has been lost to natural disaster (Hurricane Micheal), therefore there is no study data that is available to report</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Slit Lamp (Cornea Exam)</title>
        <time_frame>To end of study (1 month postop)</time_frame>
        <population>Study data has been lost to natural disaster (Hurricane Micheal), therefore there is no study data that is available to report</population>
        <group_list>
          <group group_id="O1">
            <title>Imprimis Dropless</title>
            <description>TriMoxiVanc 0.2cc intravitreal one time&#xD;
Imprimis Dropless: Tri-Moxi-Vanc transzonular intravitreal injection</description>
          </group>
          <group group_id="O2">
            <title>Imprimis Less Drops</title>
            <description>Pred Moxi, 1 drop tid for 1 week then, PredKeterolac bid for 2-4 weeks.&#xD;
Imprimis Less Drops: Pred-Moxi-Ketorolac and Pred-Ketorolac topical instillation qd postoperatively</description>
          </group>
        </group_list>
        <measure>
          <title>Slit Lamp (Cornea Exam)</title>
          <population>Study data has been lost to natural disaster (Hurricane Micheal), therefore there is no study data that is available to report</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject Reporting no Eye Pain</title>
        <description>&quot;0&quot;( on the eye pain/discomfort scale)</description>
        <time_frame>To end of study (1 month postop)</time_frame>
        <population>Study data has been lost to natural disaster (Hurricane Micheal), therefore there is no study data that is available to report</population>
        <group_list>
          <group group_id="O1">
            <title>Imprimis Dropless</title>
            <description>TriMoxiVanc 0.2cc intravitreal one time&#xD;
Imprimis Dropless: Tri-Moxi-Vanc transzonular intravitreal injection</description>
          </group>
          <group group_id="O2">
            <title>Imprimis Less Drops</title>
            <description>Pred Moxi, 1 drop tid for 1 week then, PredKeterolac bid for 2-4 weeks.&#xD;
Imprimis Less Drops: Pred-Moxi-Ketorolac and Pred-Ketorolac topical instillation qd postoperatively</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Reporting no Eye Pain</title>
          <description>&quot;0&quot;( on the eye pain/discomfort scale)</description>
          <population>Study data has been lost to natural disaster (Hurricane Micheal), therefore there is no study data that is available to report</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline Eye Pain/Discomfort</title>
        <description>eye pain/discomfort scale</description>
        <time_frame>To end of study (1 month postop)</time_frame>
        <population>Study data has been lost to natural disaster (Hurricane Micheal), therefore there is no study data that is available to report</population>
        <group_list>
          <group group_id="O1">
            <title>Imprimis Dropless</title>
            <description>TriMoxiVanc 0.2cc intravitreal one time&#xD;
Imprimis Dropless: Tri-Moxi-Vanc transzonular intravitreal injection&#xD;
no Adverse events</description>
          </group>
          <group group_id="O2">
            <title>Imprimis Less Drops</title>
            <description>Pred Moxi, 1 drop tid for 1 week then, PredKeterolac bid for 2-4 weeks.&#xD;
Imprimis Less Drops: Pred-Moxi-Ketorolac and Pred-Ketorolac topical instillation qd postoperatively&#xD;
No adverse events</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Eye Pain/Discomfort</title>
          <description>eye pain/discomfort scale</description>
          <population>Study data has been lost to natural disaster (Hurricane Micheal), therefore there is no study data that is available to report</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Proportion of Subjects Reporting no Visual Symptoms (&quot;0&quot; )</title>
        <description>visual symptom scale</description>
        <time_frame>To end of study (1 month postop)</time_frame>
        <population>Study data has been lost to natural disaster (Hurricane Micheal), therefore there is no study data that is available to report</population>
        <group_list>
          <group group_id="O1">
            <title>Imprimis Dropless</title>
            <description>TriMoxiVanc 0.2cc intravitreal one time&#xD;
Imprimis Dropless: Tri-Moxi-Vanc transzonular intravitreal injection</description>
          </group>
          <group group_id="O2">
            <title>Imprimis Less Drops</title>
            <description>Pred Moxi, 1 drop tid for 1 week then, PredKeterolac bid for 2-4 weeks.&#xD;
Imprimis Less Drops: Pred-Moxi-Ketorolac and Pred-Ketorolac topical instillation qd postoperatively</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Subjects Reporting no Visual Symptoms (&quot;0&quot; )</title>
          <description>visual symptom scale</description>
          <population>Study data has been lost to natural disaster (Hurricane Micheal), therefore there is no study data that is available to report</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Change From Baseline in Visual Symptoms</title>
        <description>visual symptom scale</description>
        <time_frame>To end of study (1 month postop)</time_frame>
        <population>Study data has been lost to natural disaster (Hurricane Micheal), therefore there is no study data that is available to report</population>
        <group_list>
          <group group_id="O1">
            <title>Imprimis Dropless</title>
            <description>TriMoxiVanc 0.2cc intravitreal one time&#xD;
Imprimis Dropless: Tri-Moxi-Vanc transzonular intravitreal injection</description>
          </group>
          <group group_id="O2">
            <title>Imprimis Less Drops</title>
            <description>Pred Moxi, 1 drop tid for 1 week then, PredKeterolac bid for 2-4 weeks.&#xD;
Imprimis Less Drops: Pred-Moxi-Ketorolac and Pred-Ketorolac topical instillation qd postoperatively</description>
          </group>
        </group_list>
        <measure>
          <title>The Change From Baseline in Visual Symptoms</title>
          <description>visual symptom scale</description>
          <population>Study data has been lost to natural disaster (Hurricane Micheal), therefore there is no study data that is available to report</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Change From Baseline in Central Corneal Thickness Measurements</title>
        <description>corneal pachymetry</description>
        <time_frame>To end of study (1 month postop)</time_frame>
        <population>Study data has been lost to natural disaster (Hurricane Micheal), therefore there is no study data that is available to report</population>
        <group_list>
          <group group_id="O1">
            <title>Imprimis Dropless</title>
            <description>TriMoxiVanc 0.2cc intravitreal one time&#xD;
Imprimis Dropless: Tri-Moxi-Vanc transzonular intravitreal injection</description>
          </group>
          <group group_id="O2">
            <title>Imprimis Less Drops</title>
            <description>Pred Moxi, 1 drop tid for 1 week then, PredKeterolac bid for 2-4 weeks.&#xD;
Imprimis Less Drops: Pred-Moxi-Ketorolac and Pred-Ketorolac topical instillation qd postoperatively</description>
          </group>
        </group_list>
        <measure>
          <title>The Change From Baseline in Central Corneal Thickness Measurements</title>
          <description>corneal pachymetry</description>
          <population>Study data has been lost to natural disaster (Hurricane Micheal), therefore there is no study data that is available to report</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Change From Baseline in Macular Thickness Measurements</title>
        <description>based on optical coherence tomography (OCT) measurement</description>
        <time_frame>To end of study (1 month postop)</time_frame>
        <population>Study data has been lost to natural disaster (Hurricane Micheal), therefore there is no study data that is available to report</population>
        <group_list>
          <group group_id="O1">
            <title>Imprimis Dropless</title>
            <description>TriMoxiVanc 0.2cc intravitreal one time&#xD;
Imprimis Dropless: Tri-Moxi-Vanc transzonular intravitreal injection</description>
          </group>
          <group group_id="O2">
            <title>Imprimis Less Drops</title>
            <description>Pred Moxi, 1 drop tid for 1 week then, PredKeterolac bid for 2-4 weeks.&#xD;
Imprimis Less Drops: Pred-Moxi-Ketorolac and Pred-Ketorolac topical instillation qd postoperatively</description>
          </group>
        </group_list>
        <measure>
          <title>The Change From Baseline in Macular Thickness Measurements</title>
          <description>based on optical coherence tomography (OCT) measurement</description>
          <population>Study data has been lost to natural disaster (Hurricane Micheal), therefore there is no study data that is available to report</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study data has been lost to natural disaster (Hurricane Micheal), therefore there is no study data that is available to report</time_frame>
      <desc>Study data has been lost to natural disaster (Hurricane Micheal), therefore there is no study data that is available to report</desc>
      <group_list>
        <group group_id="E1">
          <title>Imprimis Dropless</title>
          <description>TriMoxiVanc 0.2cc intravitreal one time&#xD;
Imprimis Dropless: Tri-Moxi-Vanc transzonular intravitreal injection&#xD;
no Adverse events</description>
        </group>
        <group group_id="E2">
          <title>Imprimis Less Drops</title>
          <description>Pred Moxi, 1 drop tid for 1 week then, PredKeterolac bid for 2-4 weeks.&#xD;
Imprimis Less Drops: Pred-Moxi-Ketorolac and Pred-Ketorolac topical instillation qd postoperatively&#xD;
No adverse events</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study data has been lost to natural disaster (Hurricane Micheal), therefore there is no study data that is available to report</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Christina Menck</name_or_title>
      <organization>Eye Center of N Florida</organization>
      <phone>8507843937 ext 1124</phone>
      <email>eyenerdgyrl1@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

